CATX
Perspective Therapeutics, Inc.
There isn't enough reported data to score CATX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CATX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
CATX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CATX PE Valuation
CATX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CATX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CATX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CATX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.25 | +$0.46 |
| Q2 2026 | -$1.33 | +$0.24 |
| Q1 2026 | -$1.40 | +$0.06 |
| Q4 2025 | -$1.40 | +$0.01 |
| Q3 2025 | -$1.71 | -$0.94 |
| Q2 2025 | -$1.57 | -$0.61 |
| Q1 2025 | -$1.46 | -$0.28 |
| Q4 2024 | -$1.41 | -$0.43 |
CATX is still losing money, but less than at its worst: $1.25 per share over the past year, against $1.71 at its worst in late 2025.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CATX on earnings quality, reporting a profit while its opponent remains loss making.
CATX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2023 | $2.2M | +27% |
| Q2 2023 | $2.1M | -17% |
| Q1 2023 | $2.1M | -29% |
| Q4 2022 | $1.8M | -35% |
| Q3 2022 | $1.7M | -33% |
| Q2 2022 | $2.5M | -7.6% |
| Q1 2022 | $2.9M | +12% |
| Q4 2021 | $2.8M | +19% |
LLY has the stronger quarterly revenue trend. Revenue is down 386% for CATX versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2023 | -482% | -237 points |
| Q2 2023 | -545% | -461 points |
| Q1 2023 | -544% | -497 points |
| Q4 2022 | -175% | -117 points |
| Q3 2022 | -245% | -156 points |
| Q2 2022 | -84% | -44 points |
| Q1 2022 | -47% | -18 points |
| Q4 2021 | -58% | -21 points |
CATX's operating margin was −482% last quarter, down 237 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
CATX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$35.9M | -$17.6M |
| Q2 2026 | -$34.8M | -$13.9M |
| Q1 2026 | -$38.3M | -$12.1M |
| Q4 2025 | -$29.7M | +$11.5M |
| Q3 2025 | -$18.3M | +$8.1M |
| Q2 2025 | -$21M | -$11.1M |
| Q1 2025 | -$26.2M | -649% |
| Q4 2024 | -$41.2M | -$32.1M |
CATX has burned cash in almost every quarter: −$139M over the past year, against −$107M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CATX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CATX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +97K shares |
| 1 year | +63% | +46.5M shares |
| 3 years | +331% | +92.7M shares |
| 5 years | +885% | +108M shares |
| Available history | +1692% | +114M shares |
CATX has 121M diluted shares, up 63% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q4 2022 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CATX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CATX Net Leverage
CATX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CATX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.9 | Oversold |
| Stochastic | 2.7 | Oversold |
CATX's weekly RSI is 24 (oversold) and its Stochastic is 3 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CATX PE vs Healthcare Sector
CATX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CATX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.82 | 54% below |
| 20 week MA | $2.57 | 67% below |
| 50 week MA | $3.29 | 74% below |
| 100 week MA | $3.19 | 74% below |
| 200 week MA | $5.58 | 85% below |
CATX is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CATX on trend strength, trading above more of its moving averages.
CATX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.12 | $4.70 | -23% |
| 2021 | $4.70 | $4.06 | -14% |
| 2022 | $4.06 | $2.90 | -29% |
| 2023 | $2.90 | $4.02 | +39% |
| 2024 | $4.02 | $3.19 | -21% |
| 2025 | $3.19 | $2.88 | -9.7% |
| 2026 YTD | $2.88 | $0.84 | -71% |
CATX has finished lower in five of the last six years. It's down 71% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CATX on returns for 2026, with the stronger performance.